Secondary Hyperparathyroidism Treatment Market 2025 | Market Growth, AI-Driven Drug Advances, CKD Focus & Regional Expansion

"Secondary Hyperparathyroidism Treatment Market reached US$ 4.3 billion in 2022 and is expected to reach US$ 8.5 billion by 2030 growing with a CAGR of 9.2% during the forecast period 2023-2030, according to DataM Intelligence research report" as per DataM intelligence research report.

Secondary Hyperparathyroidism Treatment Market: Recent Industry Developments
United States
✅ In July 2025, the U.S. SHPT treatment market is projected to reach USD 11.03 billion by 2032, fueled by technological innovation and growing R&D investment.This reflects a robust growth trajectory driven by evolving therapies and generics.It underscores expanding opportunity for treatment developers and stakeholders.
✅ In April 2022, Pathalys Pharma announced plans for a global Phase III program for Upacicalcet (PLS240) targeting SHPT in hemodialysis patients.This heralds a potential novel intravenous calcimimetic advancing through late-stage development.
It could significantly broaden SHPT therapy modalities beyond current options.
✅ In October 2020, Dr. Reddy's launched its FDA-approved generic cinacalcet (Sensipar) tablets, offering a cost-effective oral calcimimetic alternative.This expanded affordable treatment options for SHPT patients on dialysis.It intensified competition and increased patient access in the U.S. calcimimetic segment.

Japan
✅ In 2024, The Asia-Pacific region, including Japan, is emerging as the fastest-growing SHPT market due to rising CKD prevalence and healthcare investment.Japanese pharma players are positioned to leverage this growth via innovative therapies and market expansion.This trend sets the stage for future SHPT product launches in Japan.
✅ In June 2021, Upacicalcet (Upasita) received marketing authorization in Japan via a co-promotion agreement between Sanwa Kagaku Kenkyusho and Kissei Pharmaceutical.This introduced a new intravenous calcimimetic option for Japanese dialysis patients.It diversifies the treatment landscape with alternate delivery modalities.
✅ In May 2018, Kyowa Hakko Kirin launched Orkedia (evocalcet) in Japan to treat SHPT in dialysis patients.This next-generation oral calcimimetic offered improved GI tolerability over older agents.It reinforced Japan's leadership in advanced SHPT therapy adoption.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/secondary-hyperparathyroidism-treatment-market?jd

Market growth opportunities (2025-2031):

Projected trends suggest healthy expansion underpinned by personalized medicine as genetic and biomarker research catalyze the development of targeted SHPT therapies. The rise of biosimilar options offers more cost-effective treatment alternatives, particularly in emerging markets. Rapidly aging populations and the growing prevalence of chronic kidney disease (CKD) continue to elevate demand for SHPT interventions. Increasing investment in healthcare infrastructure and R&D across developing regions is broadening market access. Furthermore, telemedicine and digital health strategies are enhancing patient outreach and long-term management.

Secondary Hyperparathyroidism Treatment Market: Technological Advancements

✦ Innovations in next-generation calcimimetics, such as novel oral and injectable formulations, are offering enhanced efficacy with improved safety profiles.
✦ Development of non-calcium-based phosphate binders is underway, offering new therapeutic mechanisms that may reduce mineral imbalance side effects.
✦ Advanced biosimilars are being introduced, promoting cost-efficiency and broader access to biologic therapy options.
✦ The integration of telemedicine platforms is facilitating better patient monitoring, improving adherence and access especially in remote or underserved areas.
✦ Novel agents like Upacicalcet, a calcimimetic approved in Japan, demonstrate successful intravenous use in dialysis patients highlighting progress in precision drug delivery.

Secondary Hyperparathyroidism Treatment Market: Drivers

The rising incidence of CKD, a primary precursor of SHPT, is one of the strongest upward pressures on the market. Growing awareness among clinicians and patients further supports early intervention and treatment adoption. Advances in therapeutic options from oral agents to injectable biologics are expanding the treatment landscape beyond traditional approaches. Increased investment in SHPT drug research and expanding healthcare infrastructure in emerging markets are enhancing treatment accessibility. Finally, supportive reimbursement and regulatory frameworks in developed regions are smoothing pathways for advanced therapy uptake.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/secondary-hyperparathyroidism-treatment-market?jd

Segment Covered in the Secondary Hyperparathyroidism Treatment Market:

➥ By Drug Class: Vitamin D Analogs, Calcimimetics, Phosphate Binders, Others
➥ By Route of Administration: Oral, Intravenous, Subcutaneous
➥ By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies

Strategic Players Driving the Secondary Hyperparathyroidism Treatment Market Forward:

Major players are Amgen Inc, Tairui Biotechnology Co Ltd, Sanofi SA, Validus Pharmaceuticals LLC, AbbVie Inc, ONO PHARMACEUTICAL CO LTD, Kyowa Kirin Co Ltd., Teva Pharmaceuticals USA, Inc and Pharmanovia.

Why Purchase the Report for Secondary Hyperparathyroidism Treatment Market?

➠ Technology & Innovation: Tracks clinical trials and upcoming pharmaceutical advancements to stay ahead in product development.
➠ Market Positioning & Competitive Strategy: Analyzes product performance, market share, and competitor tactics for strategic decision-making.
➠ Real-World Evidence & Physician Insights: Incorporates patient data and physician behavior to align products with actual healthcare needs.
➠ Pricing & Market Access: Reviews reimbursement trends and access models to optimize product pricing and launch strategies.
➠ Regulatory & Industry Shifts: Covers policy changes, health system dynamics, and technology trends impacting market opportunities.
➠ Regional Growth & Expansion: Identifies high-growth markets and investment opportunities for geographic expansion.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=secondary-hyperparathyroidism-treatment-market

Regional Analysis for Secondary Hyperparathyroidism Treatment Market:

North America dominates the SHPT treatment landscape, benefiting from high CKD prevalence, strong R&D capabilities, and ready regulatory pathways. Europe follows closely, propelled by the introduction of new therapies and a broad patient base. The Asia-Pacific region is emerging rapidly with clinical trial activity, and increasing healthcare investments are expected to drive accelerated market expansion in the near term.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.